NCT07078760

Brief Summary

The LINEAR study is designed to compare the procedural efficacy, efficiency and safety of linear radiofrequency ablation of the cavotricuspid istmus using either a standar irrigated-tip ablation catheter or lattice-tip ablation catheter .The primary focus of the acute procedural data analysis will be: Procedural efficacy: This will be evaluated based on the rate of bidirectional CTI block persistence after 60 min waiting period documented by high resolution activation mapping. Furthermore, provocative test with intravenous adenosine infusion will be conducted to exclude dormant CTI conduction. Procedural efficiency: This will be evaluated based on the number of RF lesions delivered, time to achieve bidirectional CTI block, and fluoroscopy exposure time. Procedural safety: The incidence of procedural complications will be recorded.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
96

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 16, 2025

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

July 4, 2025

Completed
18 days until next milestone

First Posted

Study publicly available on registry

July 22, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

August 27, 2025

Status Verified

August 1, 2025

Enrollment Period

7 months

First QC Date

July 4, 2025

Last Update Submit

August 20, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • The primary procedural endpoint for efficacy will be the achievement of bidirectional CTI block after 60 min waiting period documented by high resolution activation mapping . The primary safety endpoint will be the incidence of procedural complications.

    The primary procedural endpoint for efficacy will be the achievement of bidirectional CTI block. After completion of the CTI line, bidirectional block will be confirmed through differential pacing maneuvers followed by activation mapping, performed using the Affera mapping system for Group A and the CARTO mapping system for Group B, respectively. Activation mapping will be repeated 60 minutes after the initial documentation of bidirectional block to assess for its persistence or the presence of spontaneous recovery of CTI conduction. In the absence of spontaneous recovery, a provocative test involving intravenous adenosine infusion will be conducted to evaluate for dormant CTI conduction. During the adenosine infusion and the resultant transient atrioventricular block or sinus pause, bidirectional block will be reassessed using differential pacing maneuvers with the mapping catheter positioned laterally to the ablation line.The incidence of procedural complications will be recorded.

    60 minutes

Study Arms (2)

CTI radiofrequency ablation with lattice-tip catheter

ACTIVE COMPARATOR

Patients undergoing CTI catheter ablation using RF energy delivered by the lattice-tip, dual-energy catheter (Sphere-9, Medtronic).

Procedure: CTI radiofrequency ablation.

CTI radiofrequency ablation performed with irrigated-tip catheter

ACTIVE COMPARATOR

Patients undergoing CTI catheter ablation using RF energy delivered by the irrigated RF catheter (ThermoCool® SmartTouch™, Biosense Webster, USA).

Procedure: CTI radiofrequency ablation.

Interventions

Cavotricuspid Isthmus ablation

CTI radiofrequency ablation performed with irrigated-tip catheterCTI radiofrequency ablation with lattice-tip catheter

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients above 18 years of age undergoing CTI ablation

You may not qualify if:

  • Prior right atrium ablation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mitera General Hospital

Athens, Attikis, 11523, Greece

RECRUITING

Study Officials

  • Stylianos Tzeis, MD, PhD, FEHRA

    Mitera Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Stylianos Tzeis, MD, PhD, FEHRA

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD, FEHRA, Cardiologist - Electrophysiologist

Study Record Dates

First Submitted

July 4, 2025

First Posted

July 22, 2025

Study Start

June 16, 2025

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

August 27, 2025

Record last verified: 2025-08

Locations